Investment Thesis
Microbot 1-year share price performance. Source: TradingView.
Microbot (NASDAQ:MBOT) is a thinly traded stock but I believe the company has plenty to offer, based on its innovative products, experienced management team and current funding position.
The company has accessed the NASDAQ through the back door, via a merger with StemCells in 2016, whose share price had collapsed prior to the merger. Despite some teething issues, which has resulted in ongoing litigation that has partially gone against the company, Microbot has successfully secured funding of ~$30m, whilst also progressing 3 innovative products